本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Apellis Pharmaceuticals Inc.

27.80
-0.3700-1.31%
盤後27.40-0.4000-1.44%17:20 EDT
成交量:308.47萬
成交額:8,586.36萬
市值:35.11億
市盈率:-15.24
高:28.60
開:28.14
低:27.56
收:28.17
52周最高:41.94
52周最低:16.10
股本:1.26億
流通股本:7,811.99萬
量比:1.91
換手率:3.95%
股息:- -
股息率:- -
每股收益(TTM):-1.8245
每股收益(LYR):-1.5970
淨資產收益率:-108.49%
總資產收益率:-13.77%
市淨率:22.46
市盈率(LYR):-17.41

資料載入中...

2024/12/23

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/12/11

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/11/22

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/22

超過5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/11/08

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/05

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/09/16

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/09/03

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/08

重要事件披露

Form 8-K - Current report
2024/08/01

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/06/21

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/06/05

重要事件披露

Form 8-K - Current report
2024/05/14

重要事件披露

Form 8-K - Current report
2024/05/09

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/05/07

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/04/09

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/04/01

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/03/20

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/03/19

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/03/15

關聯方擬減持公告

Form 144 - Report of proposed sale of securities